Surface qualified second-source candidates for any concentrated lane. Active exporter footprint, recent volume, plant inspection class — ranked in one query.
Mesalamine on the India to US lane is dominated by Cadila with $181.5M in cumulative export value across 275 shipments since 2023. Six smaller exporters carry the long tail. Sun Pharma is the meaningful second name with $15M historical volume. Ipca, Annora, Encube, and BEC Chemicals sit below $7M cumulative; the dual-source question on this lane is between Sun Pharma at scale or qualifying multiple long-tail exporters at lower volume.
| # | Exporter | Origin | Cumulative trade | Shipments | Posture |
|---|---|---|---|---|---|
| 1 | Cadila | IN · multi-plant | 275 shipments | $181.5M | NAI |
| 2 | Sun Pharmaceutical Industries | IN · Halol | 167 shipments | $14.95M | OAI |
| 3 | Ipca Laboratories | IN · Chandigarh | 94 shipments | $6.29M | NAI |
| 4 | Annora | IN · Hyderabad | 16 shipments | $3.38M | VAI |
| 5 | Encube | IN · Mumbai | 58 shipments | $2.72M | NAI |
The molecule, origin, and destination. Usually run after a Lane Concentration Risk analysis flags HHI ≥ 0.40.
Active exporters on the lane joined to historical export volume, recent shipment count, and inspection class for the matched plant.
Citation-anchored brief with each candidate's volume, recent year activity, and a posture chip — qualify, watch, or deprioritise.
Each candidate is filtered to recent activity on the lane. Paper-only exporters with stale shipments are pushed to the secondary list.
Cumulative trade and shipment counts are the ranking signal. A candidate with $10M shipped is qualified differently than one with $50k.
Plants with OAI classification surface with a red chip. NAI / VAI / OAI is a first-cut gate before qualification work.
The lane's concentration metric is shown alongside the exporter list. A 0.85 HHI lane with 7 exporters has a different playbook than a 0.40 HHI lane with 12.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Eighteen molecule-lanes from the live warehouse · active exporters on the highest-value lane per molecule, 2024.
The dual-source workflow is the standard follow-up to a Lane Concentration Risk finding. PharmaDB joins active exporters on the lane to historical volume, recent activity, and inspection class — and returns a ranked outreach order. The view is company_trade_exports_by_molecule; the underlying tables are molecule_country_flow, lane_competitiveness, and inspections.
An exporter on the same molecule-lane with recent shipment activity, a regulatory dossier for the destination market, and a clean recent inspection at the manufacturing plant. PharmaDB applies all three signals at the query layer and surfaces missing fields as flags.
Total declared export value per exporter on the lane, summed over the trailing 24 months. Shipment count is reported alongside value to give a sense of frequency. Both come from `company_trade_exports_by_molecule`.
No — they surface with a red inspection chip and remain visible to the buyer. The mesalamine example shows Sun Pharma with an OAI Halol flag; the buyer's qualification team makes the call whether to proceed with mitigation steps.
The page surfaces zero qualified second sources and recommends the upstream Lane Substitution Playbook — qualifying a different origin country, or a different intermediate API route.
Yes. Same methodology applies to API, FDF, and intermediates. FDF lanes add a regulatory check for the local marketing authorisation, surfaced as a separate column.
Trade aggregates and inspections refresh weekly. Each candidate row carries its most-recent regulatory and inspection status timestamp. The page footer carries the catalog refresh time.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.